Preclinical Data Show Alfacell's ONCONASE(R) Inhibits Tumor Growth Of Non-Small Cell Lung Cancer, Breast Cancer Cells

Alfacell
Corporation (Nasdaq: ACEL) today announced that in vivo and in vitro
preclinical data presented in a poster at the American Association for
Cancer Research (AACR) Annual Meeting show that ONCONASE (ranpirnase)
significantly inhibits tumor growth of non-small cell lung cancer (NSCLC)
and breast cancer cells.



In the poster titled "Increased apoptosis and reduced lactate levels by
ranpirnase in human lung and breast cancer", Intae Lee, Ph.D. and
collaborators at the University of Pennsylvania demonstrated that ONCONASE
significantly inhibited tumor growth by inducing apoptosis (cell death) in
A549 and NCI-H1975 human NSCLC cells and MDA-MB-231 and MCF-7 human breast
cancer cells without damaging non-cancerous cells such as HLF-1 human lung
fibroblast and NCI/3T3 fibroblast. Additionally, the data indicated that
twice weekly injections of ONCONASE were more effective than an equivalent
single dose injection in these tumor types.



"The findings of our investigation suggest important potential clinical
uses of ONCONASE for the treatment of NSCLC and breast cancer," said Dr.
Lee.



Kuslima Shogen, Alfacell's chairman and chief executive officer, added:
"This research adds to the extensive published data that supports our
continued development of ONCONASE for multiple cancer indications. The
ONCONASE franchise includes the gateway indication of malignant
mesothelioma and several other tumor types for which we are continuing
preclinical and clinical studies."



About ONCONASE(R)



ONCONASE is a first-in-class therapeutic product candidate based on
Alfacell's proprietary ribonuclease (RNase) technology. A natural protein
isolated from the leopard frog, ONCONASE has been shown in the laboratory
and clinic to target cancer cells while sparing normal cells. ONCONASE
triggers apoptosis, the natural death of cells, via multiple molecular
mechanisms of action.



About Alfacell Corporation



Alfacell Corporation is the first company to advance a
biopharmaceutical product candidate that works in a manner similar to RNA
interference (RNAi) through late-stage clinical trials. The product
candidate, ONCONASE, is an RNase that overcomes the challenges of targeting
RNA for therapeutic purposes while enabling the development of a new class
of targeted therapies for cancer and other life-threatening diseases. In
addition to an ongoing Phase IIIb study in malignant mesothelioma, Alfacell
is conducting a Phase I/II trial of ONCONASE in non-small cell lung cancer
(NSCLC) and other solid tumors. For more information, visit
alfacell.



Safe Harbor



This press release includes statements that may constitute "forward-
looking" statements, usually containing the words "believe," "estimate,"
"project," "expect" or similar expressions. Forward-looking statements
involve risks and uncertainties that could cause actual results to differ
materially from the forward-looking statements. Factors that would cause or
contribute to such differences include, but are not limited to,
uncertainties involved in transitioning from concept to product,
uncertainties involving the ability of the company to finance research and
development activities, potential challenges to or violations of patents,
uncertainties regarding the outcome of clinical trials, the company's
ability to secure necessary approvals from regulatory agencies, dependence
upon third-party vendors, and other risks discussed in the company's
periodic filings with the Securities and Exchange Commission. By making
these forward-looking statements, the company undertakes no obligation to
update these statements for revisions or changes after the date of this
release.


Alfacell Corporation

alfacell

Buy Anti-Bacterial Face Mask Without Prescription